Abstract 1785P
Background
Androgen deprivation therapy (ADT) is associated with increased fracture risk, due to bone loss and bone quality impairment, as well as with profound alterations in body composition favoring the transition to sarcopenic obesity. Additional metabolic effects of next generation hormonal agents (NGHA) in combination with ADT have been poorly studied.
Methods
BonEnza (NCT03336983) is a prospective phase II trial in which mHSPC patients were randomized to receive either ADT plus enzalutamide (E arm) or the same combination with the addition of zoledronic acid (EZ arm). Bone mineral density (BMD), trabecular bone score (TBS), fat body mass (FBM) and lean body mass (LBM) were assessed at baseline and after 18 months using dual energy x-ray absorptiometry (DEXA) scan.
Results
From February 2018 to December 2022, a total of 89 patients (46 from EZ arm and 43 from E arm), had paired DEXA evaluation at both timepoints. Femoral BMD and TBS significantly reduced in E arm (-9.1%, p<0.001; -3.1%, p=0.001, respectively), while they increased in EZ arm (5.3%, p<0.001; 2.8%, p=0.008, respectively). FBM increased by 22.7% (p<0.001) and LBM decreased by 6.3% (p<0.001) after 18 months of therapy, irrespective of study arm.
Conclusions
The addition of enzalutamide to ADT is associated with a marked reduction in BMD and impaired bone quality as measured by TBS. Both effects are prevented by zoledronic acid administration. The reduction in LBM and increase in FBM were doubled compared to previous observations with ADT alone, putting patients at an elevated risk of sarcopenic obesity.
Clinical trial identification
NCT03336983.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Astellas.
Disclosure
A. Dalla Volta: Financial Interests, Personal, Advisory Board: Janssen; Financial Interests, Institutional, Research Funding: Janssen, Ipsen, Astellas. All other authors have declared no conflicts of interest.
Resources from the same session
1219P - Artificial intelligence-based breast cancer detection facilitates automated prognosis marker assessment using multiplex fluorescence immunohistochemistry
Presenter: Tim Mandelkow
Session: Poster session 14
1220P - Comprehensive diagnose of programmed death-ligand 1 from two-dimensional to three-dimensional in breast cancer with computer-aided artificial intelligence system
Presenter: Yi-Hsuan Lee
Session: Poster session 14
1221P - The functional domain of BRCA1/2 pathogenic variants (PVs) as potential biomarkers of second tumor and domain-related sensitivity to PARP-inhibitors
Presenter: Lorena Incorvaia
Session: Poster session 14
1222P - Detection of androgen-receptor splice variant 7 messenger RNA in circulating tumor cells of prostate cancer by in vitro assay
Presenter: Hoin Kang
Session: Poster session 14
1223P - Homologous recombination deficiency (HRD) testing on ovarian cancer ascites: A feasibility study
Presenter: Alberto Ranghiero
Session: Poster session 14
1224P - Detection of circulating tumor DNA (ctDNA) in untreated patients (pts) with cancer: Implications for early cancer detection (ECD)
Presenter: Yoshiaki Nakamura
Session: Poster session 14
1225P - Combining ctDNA and tissue-based-genomic profiling in advanced cancer: A real-world evidence prospective study in non-Western patients treated at Gustave Roussy cancer campus
Presenter: Tony Ibrahim
Session: Poster session 14
1226P - Multi-site validation of a deep learning solution for HER2 profiling of breast cancer from H&E-stained pathology slides
Presenter: Salim Arslan
Session: Poster session 14
1227P - Novel in vivo photonics-immunoassay system, inPROBE, for the rapid detection of HER2 in breast cancer
Presenter: Magdalena Staniszewska
Session: Poster session 14
1228P - A circulating tumor cell (CTC) based assay for diagnostic immunocytochemistry profiling of lung cancer
Presenter: Nitesh Rohatgi
Session: Poster session 14